Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

[U.S. News]

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

Continue reading...